Literature DB >> 3909636

Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions.

M Fisher, J R Chapman, A Ting, P J Morris.   

Abstract

24 previously non-transfused patients were given three transfusions of 200 X 10(8) platelets at 14-day intervals. Group I (12 patients) received leucocyte-poor platelet suspensions with a mean contamination of 15 X 10(6) leucocytes per transfusion. Group II (12 patients) received platelets with less than 5 X 10(6) leucocytes per transfusion. 5 patients in group I and no patients in group II developed lymphocytotoxic antibodies (p = 0.037). Platelets with fewer than 5 X 10(6) leucocytes did not seem to stimulate a response to major histocompatibility antigens, but with a small contaminating dose of leucocytes appeared to be highly immunogenic.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3909636     DOI: 10.1111/j.1423-0410.1985.tb00807.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  13 in total

1.  In vitro evaluation of a high-efficiency leukocyte adherence filter.

Authors:  M K Elias; J W Smit; M Weggemans; L Rijskamp; H Carper; R L McShine; R Brons; J Pietens; M R Halie; C T Smit Sibinga
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

2.  Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response.

Authors:  Rachael P Jackman; Xutao Deng; Douglas Bolgiano; Garth H Utter; Cathy Schechterly; Mila Lebedeva; Eva Operskalski; Naomi L Luban; Harvey Alter; Michael P Busch; Sherrill J Slichter; Philip J Norris
Journal:  Transfusion       Date:  2013-06-30       Impact factor: 3.157

3.  Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice.

Authors:  Johnson Q Tran; Marcus O Muench; Rachael P Jackman
Journal:  Blood Adv       Date:  2020-11-10

4.  Allogeneic major histocompatibility complex antigens are necessary and sufficient for partial tolerance induced by transfusion of pathogen reduced platelets in mice.

Authors:  Johnson Q Tran; Marcus O Muench; John W Heitman; Rachael P Jackman
Journal:  Vox Sang       Date:  2019-02-07       Impact factor: 2.144

5.  Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.

Authors:  Rachael P Jackman; Marcus O Muench; Heather Inglis; John W Heitman; Susanne Marschner; Raymond P Goodrich; Philip J Norris
Journal:  Transfusion       Date:  2016-11-18       Impact factor: 3.157

6.  Sensitization from transfusion in patients awaiting primary kidney transplant.

Authors:  Julie M Yabu; Matthew W Anderson; Deborah Kim; Brian D Bradbury; Calvin D Lou; Jeffrey Petersen; Jerome Rossert; Glenn M Chertow; Dolly B Tyan
Journal:  Nephrol Dial Transplant       Date:  2013-09-05       Impact factor: 5.992

7.  A comparison of different methods of red blood cell leukoreduction and additive solutions on the accumulation of neutrophil-priming activity during storage.

Authors:  Michele M Loi; Marguerite Kelher; Monika Dzieciatkowska; Kirk C Hansen; Anirban Banerjee; F Bernadette West; Crystal Stanley; Matthew Briel; Christopher C Silliman
Journal:  Transfusion       Date:  2018-09-01       Impact factor: 3.157

8.  Serological findings and efficiency of DNA profiling in transfused patients and their significance for identity and paternity tests.

Authors:  W Huckenbeck; S Rand
Journal:  Int J Legal Med       Date:  1994       Impact factor: 2.686

9.  Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants.

Authors:  Rachael P Jackman; Xutao Deng; Douglas Bolgiano; Mila Lebedeva; John W Heitman; Michael P Busch; Sherrill J Slichter; Philip J Norris
Journal:  Blood       Date:  2013-02-07       Impact factor: 22.113

10.  C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.

Authors:  Rachael P Jackman; Jar-How Lee; Rui Pei; Douglas Bolgiano; Mila Lebedeva; Sherrill J Slichter; Philip J Norris
Journal:  Transfusion       Date:  2016-04-15       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.